All In Biotech

Drug Trial Radar · NCT05761431

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

A Single-dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Octreotide Injection in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Oct 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Mar 2, 2023

Primary completion

Jun 28, 2023

Study completion Jun 28, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 22 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-centre, single-dose, dose-escalation, placebo and positive drug-controlled Phase I clinical study in healthy Chinese subjects to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of octreotide injection in healthy Chinese subjects.

Conditions

  • Acromegaly

Interventions

  • SYHX2008 injectionDrug

    Subcutaneous administration on Day 1.

  • Octreotide Acetate Microspheres for Injection injectionDrug

    Intramuscular administration on Day 1.

  • Sandostatin ® injectionDrug

    Subcutaneous administration on Day 1.

  • Placebo to SYHX2008 injectionDrug

    Subcutaneous administration on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse eventsTime frame: Throughout the study period, with an average of 60 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.